Claims for Patent: 7,442,830

Summary for Patent: 7,442,830

Title:	Proteasome inhibitors
Abstract:	The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Inventor(s):	Olhava; Edward J. (Cambridge, MA), Danca; Mihaela Diana (Mendham, NJ)
Assignee:	Millenium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	11/890,412
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,442,830
Patent Claims:	1. A compound of formula (I): ##STR00009## or a pharmaceutically acceptable salt or boronic acid anhydride thereof, wherein: Z.sup.1 and Z.sup.2 are each independently hydroxy, alkoxy, aryloxy, or aralkoxy; or Z.sup.1 and Z.sup.2 together form a moiety derived from a boronic acid completing agent; and Ring A is selected from the group consisting of ##STR00010## 2. The compound of claim 1 selected from the group consisting of: [(1R)-1-({[(2,3-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(5-chloro-2-fluorobenzoyl)amino]acetyl}amino)-3-methylbu- tyl]boronic acid; [(1R)-1-({[(3,5-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,5-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(2-bromobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2-chloro-5-fluorobenzoyl)amino]acetyl}amino)-3-methyl- butyl]boronic acid; [(1R)-1-({[(4-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(3,4-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(3-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(3,4-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(3-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2-chloro-4-fluorobenzoyl)amino]acetyl}amino)-3-methyl- butyl]boronic acid; [(1R)-1-({[(2,3-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2,4-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl- ]boronic acid; [(1R)-1-({[(4-chloro-2-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]bo- ronic acid; [(1R)-1-({[(4-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,4-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; and [(1R)-1-({[(3,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; or a pharmaceutically acceptable salt or boronic acid anhydride thereof. 3. The compound of claim 1, which is a mannitol ester of a boronic acid compound selected from the group consisting of: [(1R)-1-({[(2,3-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(5-chloro-2-fluorobenzoyl)amino]acetyl}amino)-3-methylbu- tyl]boronic acid; [(1R)-1-({[(3,5-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,5-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(2-bromobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2-chloro-5-fluorobenzoyl)amino]acetyl}amino)-3-methyl- butyl]boronic acid; [(1R)-1-({[(4-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(3,4-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(3-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(3,4-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(3-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2-chloro-4-fluorobenzoyl)amino]acetyl}amino)-3-methyl- butyl]boronic acid; [(1R)-1-({[(2,3-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2,4-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl- ]boronic acid; [(1R)-1-({[(4-chloro-2-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]bo- ronic acid; [(1R)-1-({[(4-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,4-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; and [(1R)-1-({[(3,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid. 4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 5. A method for treating cancer, comprising administering to a patient in need of such treatment a pharmaceutical composition according to claim 4. 6. The compound [(1R)-1({[(2,4-dichlorobenzoyl)amino]acetyl{-amino)-3-methylbutyl]boronic acid or a pharmaceutically acceptable salt or boronic acid anhydride thereof. 7. The compound [(1R)-1-({[(2,3-dichlorobenzoyl)amino]acetyl{-amino)-3-methylbutyl]boroni- c acid or a pharmaceutically acceptable salt or boronic acid anhydride thereof. 8. The compound [(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl{-amino)-3-methylbutyl]boroni- c acid or a pharmaceutically acceptable salt or boronic acid anhydride thereof. 9. The compound [(1R)-1-({[(4-chloro-2-fluorobenzoyl)amino]-acetyl{amino)-3-methylbutyl]b- oronic acid or a pharmaceutically acceptable salt or boronic acid anhydride thereof. 10. The compound [(1R)-1-({[(5-chloro-2-fluorobenzoyl)amino]acetyl{-amino)-3-methylbutyl]b- oronic acid or a pharmaceutically acceptable salt or boronic acid anhydride thereof.